Remote Patient Monitoring (RPM) Market worth $56.94 billion by 2030
Browse 354 market data Tables and 64 Figures spread through 395 Pages and in-depth TOC on "Remote Patient Monitoring (RPM) Market by Offering (Software, integrated device), Device (Wearable, implants, handheld), Function (Cardiac, Glucose, Multiparameter), Application (Diabetes, Cardio, Neuro), End user, & Region - Global Forecast to 2030
The global US Remote Patient Monitoring Market, valued at US$14.15 billion in 2024, is forecasted to grow at a robust CAGR of 12.8%, reaching US$29.13 billion by 2030. The growing number of elderly individuals and the increasing demand for cost-effective healthcare solutions are key drivers of the remote patient monitoring (RPM) market in the US. According to the Population Reference Bureau, US population aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, marking a 47% increase. During this period, the share of seniors in the total population is projected to rise from 17% to 23%. For example, US companies such as Boston Scientific Corporation, Abbott, and Dexcom enhance RPM through digital biomarkers and AI-driven analytics. Government initiatives, including Medicare reimbursement for RPM services and the CMS Hospital-at-Home program, further accelerate adoption.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=77155492
By Based on component, the US remote patient monitoring market has been segmented into devices, software and services. In 2023, device segment is estimated to hold the largest share in the US remote patient monitoring market. Recent innovations in the US remote patient monitoring (RPM) market such as in March 2024, Dexcom (US) receives FDA clearance for Stelo a glucose biosensor. The device is connected to a smartphone for continuous glucose monitoring. Furthermore, the American Hospital Association supports the remote care delivery across state lines. These initiatives collectively aim to enhance patient care through improved access and technology integration in healthcare systems
By patients' segment, the fastest growth in the US remote patient monitoring market due to the rising patient awareness, increase in the prevalence of chronic diseases rises, and growing preference for home health care. The advancements in wearable technology and mobile health applications have made it easier for patients to engage with their health data actively. For instance, in August 2023, GE HealthCare (US) received 510(k) clearance from the US FDA for its Portrait Mobile wireless and wearable monitoring solution that provides personalized view of patient vitals. The US RPM market is expanding further due to the rising demand for affordable healthcare solutions, especially as the aging population becomes increasingly comfortable with technology.
By Based on indication, the US remote patient monitoring market has been segmented into cardiology, diabetes, oncology, neurology, sleep disorders, wellness improvement, respiratory disorders, mental health, and other indications. The cardiology segment holds the largest share in the US remote patient monitoring market due to the increase in the cardiovascular diseases, and advancements in products that provide real-time cardiac data. According to the American Heart Association, approximately 2,300 people die from cardiovascular diseases (CVDs) each day in the US alone and according to the WHO, every year, CVDs cause 17.9 million deaths worldwide. Further improvements, such as in June 2024, AliveCor, Inc. (US) announced FDA clearance for Kardia 12L ECG system that detect 35 cardiac determinations, including heart attacks, using a reduced lead set.
Some of the prominent players in the US remote patient monitoring market includes GE HealthCare (US), Oracle (US), Boston Scientific Corporation (US), VitalConnect (US), Abbott (US), Optum, Inc (US), Blue Spark Technologies (US), Lightbeam (US) and others.
For more information, Inquire Now!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
22 minutes ago
- Globe and Mail
Got $1,000 to Invest in August? These High-Yielding Dividend Stocks Could Turn It Into Nearly $60 of Annual Passive Income.
Key Points EPR Properties pays a monthly dividend yielding over 6%. Vici Properties' payout yields more than 5%. The REITs expect to continue increasing their dividend payments. 10 stocks we like better than EPR Properties › Investing in high-yield dividend stocks is a great way to generate passive income. For example, investing $1,000 in the following companies could yield nearly $60 of annual dividend income: EPR Properties (NYSE: EPR) $500 6.42% $32.10 Vici Properties (NYSE: VICI) $500 5.29% $26.45 Total $1,000 5.85% $58.55 Data sources: Google Finance and author's calculations. Dividend yields are as of July 31. Here's a closer look at these high-quality, high-yielding dividend stocks. EPR Properties EPR Properties is a real estate investment trust (REIT) focused on experiential real estate. The company owns a diversified portfolio of movie theaters, eat-and-play venues, health and fitness properties, attractions, and other entertainment spaces. It leases these properties back to operating tenants, primarily under long-term, triple net leases (NNN s). Those leases provide it with very stable cash flow because tenants cover all property operating costs (including routine maintenance, real estate taxes, and building insurance). The REIT expects its stable portfolio to generate $5 to $5.16 per share of funds from operations (FFO) as adjusted this year. That easily covers its monthly dividend payment of $0.295 per share, or $3.54 annually. It also provides a cushion and surplus cash to invest in more experiential properties. EPR Properties invested $86.3 million into new properties in the first half of this year. Recent investments included acquiring land for $1.2 million and providing $5.9 million in mortgage financing secured by improvements at a health and wellness property in Georgia. It also acquired land for a new eat-and-play property development in Virginia for $1.6 million, which has an expected total cost of $19 million and an anticipated completion in 2026. The company plans to invest $200 million to $300 million in new properties this year. This includes $106 million for experiential development and redevelopment projects it plans to fund over the next 18 months. These investments should grow EPR's FFO and dividend. The REIT raised its payout by 3.5% earlier this year. Vici Properties Fellow REIT Vici Properties also invests in experiential real estate. However, its primary focus is on market-leading gaming, hospitality, wellness, entertainment, and leisure destinations. For example, it owns several iconic casinos along the Las Vegas Strip, including Caesars Palace Las Vegas, MGM Grand, and the Venetian Resort Las Vegas. The REIT also leases its properties under long-term NNN contracts with operating tenants. These leases currently have a weighted average remaining term of over 40 years. A growing subset of its leases -- 42% this year, rising to 90% by 2035 -- link rents to inflation. Its strategy of investing in large properties with long-term, inflation-linked leases provides it with stable and rising rental income. Vici Properties currently pays out $0.4325 per share each quarter in dividends, for a total of $1.73 annually. It produces plenty of cash to cover that payment level -- $2.35 to $2.37 per share of adjusted FFO is expected this year. The REIT uses the cash it retains to invest in additional experiential properties. The company has secured two notable new investments this year. It has agreed to provide a loan of up to $510 million to fund the development of the North Fork Mono Casino & Resort in California. Additionally, Vici has committed to investing $450 million into a mezzanine loan related to the development of One Beverly Hills, a landmark luxury mixed-use development in California. Vici's new investments help drive growth in both its FFO per share and its dividend. The REIT has raised its payment for seven straight years (each year since its formation). It has grown the payout at a 7.4% compound annual rate during that period, outpacing the 2.3% average of other REITs focused on properties secured by NNNs. Excellent ways to generate passive dividend income EPR Properties and Vici Properties own diversified and growing portfolios of experiential real estate. Those properties provide them with rising streams of rental income to pay dividends and invest in additional properties. That makes them great ways to turn $1,000 into a growing stream of passive dividend income this August. Should you invest $1,000 in EPR Properties right now? Before you buy stock in EPR Properties, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and EPR Properties wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
Globe and Mail
an hour ago
- Globe and Mail
Opendoor Regains Nasdaq Compliance, Cancels Stockholder Meeting
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Opendoor Technologies ( (OPEN)) just unveiled an update. On July 31, 2025, Opendoor Technologies Inc. announced it regained compliance with Nasdaq's minimum bid price requirement, as its stock maintained a closing bid price of at least $1.00 for 12 consecutive business days. Consequently, the company canceled a Special Meeting of Stockholders scheduled for August 27, 2025, which was intended to discuss a reverse stock split, as the Board deemed it unnecessary following the regained compliance. The most recent analyst rating on (OPEN) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Opendoor Technologies stock, see the OPEN Stock Forecast page. Spark's Take on OPEN Stock According to Spark, TipRanks' AI Analyst, OPEN is a Neutral. Opendoor Technologies faces significant financial challenges with declining revenues and negative earnings, leading to a low valuation score. However, technical analysis shows some positive momentum, and the company's strategic initiatives highlighted in the earnings call provide a cautiously optimistic outlook. The overall score reflects these mixed factors, with financial performance being the most significant constraint. To see Spark's full report on OPEN stock, click here. Opendoor Technologies Inc. is a leading e-commerce platform focused on residential real estate transactions, providing a simplified and certain way for people across the U.S. to sell and buy homes. The company operates nationwide and aims to innovate the future of real estate. Average Trading Volume: 175,164,562 Technical Sentiment Signal: Hold Current Market Cap: $1.34B For an in-depth examination of OPEN stock, go to TipRanks' Overview page.
Globe and Mail
an hour ago
- Globe and Mail
RCKT Deadline: Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025. Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) RP-A501 was less effective than defendants had led investors to believe; (2) to increase its effectiveness, Rocket Pharmaceuticals amended RP-A501's clinical trial protocol by introducing a novel immunomodulatory agent; (3) the foregoing increased the risk that patients would suffer from a Serious Adverse Event ('SAE'); (4) accordingly, RP-A501's safety, as well as its clinical, regulatory, and commercial prospects, were overstated; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Rocket Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 11, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.
